医学创新论坛第62期
CIMR Wednesday Lecture Series
时间:2025年3月19日(周三)下午16:00
地点:首都医科大学基础科研楼北楼二层多功能厅
主持人:
黄亚平
首都医学科学创新中心
报告人:
郑撼球
清华大学基础医学院
报告题目:
Dissecting the tumor-stromal interaction in metastasis and immune therapy resistance
摘要:
Tumor cells depend on the microenvironment for support, influencing metastasis, immune evasion, and therapy resistance. We have identified key mediators, including LTβ-LTβR and Jagged1-Notch in bone metastasis, and uncovered a metabolic interaction between osteoclasts and tumor cells that drives PARP inhibitor resistance. In our more recent work, our CRISPR-a sgRNA library screening, focused on signaling pathways, identified MALT1 as a dual-functional immune evasion gene. MALT1 promotes immune evasion through its paracaspase and death domain. In a paracaspase-dependent manner, MALT1 protects CD274 mRNA from degradation by its cleavage of ROQUIN1 and ROQUIN2. In a death-domain-dependent manner, MALT1 promotes the proliferation and polarization of tumor-associated macrophages to generate an immunosuppressive tumor microenvironment. Targeting MALT1 with antisense oligonucleotides inhibits PD-L1 expression in patient-derived tumor cells and suppresses the proliferation and M2-like polarization of tumor-associated macrophages isolated from patients with cancer. In preclinical models of solid tumors in female mice, treatment with MALT1 antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors. Together, our study demonstrates that targeting MALT1 is a potential strategy to overcome immune-checkpoint inhibitor resistance. These findings enhance our understanding of tumor-stroma interactions, highlighting promising therapeutic targets and potential synergistic treatment strategies for further exploration.
代表性论文:
1. Wang X, Zhang T, Zheng B, Lu Y, Liang Y, Xu G, Zhao L, Tao Y, Song Q, You H, Hu H, Li X, Sun K, Li T, Zhang Z, Wang J, Lan X, Pan D, Fu YX, Yue B, Zheng H. Lymphotoxin-β promotes breast cancer bone metastasis colonization and osteolytic outgrowth. Nat Cell Biol. 2024 Sep; 26(9): 1597-1612.
2. Fan H, Xu Z, Yao K, Zheng B, Zhang Y, Wang X, Zhang T, Li X, Hu H, Yue B, Hu Z, Zheng H. Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer. Cancer Res. 2024 Feb 1; 84(3): 449-467.
3. Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun HT, Coxon A, Lee B, Kang Y. Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 2017 Dec 11; 32(6): 731-747.e6.